Ontruzant® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL

Before prescribing ONTRUZANT, please read the accompanying
Prescribing Information, including the Boxed Warning about cardiomyopathy,
infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.


THE ORGANON PATIENT ASSISTANCE PROGRAM

The Organon Access Program representatives can refer patients to the Organon Patient Assistance Program.

Who is the program for?

Patients who do not have insurance, or who cannot afford their prescribed Organon medicine even with prescription drug coverage, may be eligible for free product from the Organon Patient Assistance Program if they meet certain financial, medical, and/or insurance criteria.

Getting started is simple
  1. Download and complete the appropriate sections of the enrollment form, OR use the electronic enrollment form.
  2. Submit electronically, or print and fax the completed downloadable form to 800-538-5812.
  3. A program representative will contact your patient and your office.


 WELCOME TO

Welcome to The Organon Access Program for ONTRUZANT® (trastuzumab-dttb)

ARE YOU A US HEALTH CARE PROFESSIONAL?

Please choose